Shares of Mirati Therapeutics, Inc. (NASDAQ:MRTX) have been given a consensus rating of “Buy” by the twelve ratings firms that are presently covering the firm, MarketBeat reports. Three analysts have rated the stock with a hold recommendation, eight have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $14.75.
Several research analysts recently issued reports on the company. BidaskClub raised Mirati Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, February 8th. ValuEngine raised Mirati Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Zacks Investment Research raised Mirati Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, November 7th. Oppenheimer reaffirmed a “buy” rating and set a $18.00 target price on shares of Mirati Therapeutics in a research report on Wednesday, November 22nd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $17.00 target price (down previously from $20.00) on shares of Mirati Therapeutics in a research report on Tuesday, November 14th.
Mirati Therapeutics (NASDAQ MRTX) traded up $1.00 during midday trading on Tuesday, hitting $28.35. The stock had a trading volume of 438,900 shares, compared to its average volume of 471,278. The company has a market capitalization of $738.28, a P/E ratio of -9.12 and a beta of 2.17. Mirati Therapeutics has a 52-week low of $2.70 and a 52-week high of $30.50.
In other Mirati Therapeutics news, SVP Jamie Christensen sold 10,814 shares of the business’s stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $27.00, for a total value of $291,978.00. Following the transaction, the senior vice president now owns 13,691 shares of the company’s stock, valued at $369,657. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In the last three months, insiders sold 61,039 shares of company stock worth $1,646,881. Insiders own 5.10% of the company’s stock.
A number of hedge funds have recently bought and sold shares of MRTX. Raymond James Financial Services Advisors Inc. purchased a new position in Mirati Therapeutics in the fourth quarter worth $207,000. Citadel Advisors LLC bought a new position in Mirati Therapeutics during the 3rd quarter worth $268,000. Goldman Sachs Group Inc. increased its position in Mirati Therapeutics by 845.4% during the 2nd quarter. Goldman Sachs Group Inc. now owns 98,251 shares of the biotechnology company’s stock worth $359,000 after buying an additional 87,858 shares during the period. Virtus Fund Advisers LLC bought a new position in Mirati Therapeutics during the 4th quarter worth $361,000. Finally, OxFORD Asset Management LLP bought a new position in Mirati Therapeutics during the 3rd quarter worth $365,000. 67.85% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: This story was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another website, it was illegally copied and republished in violation of US and international copyright and trademark laws. The original version of this story can be accessed at https://www.dispatchtribunal.com/2018/02/23/brokerages-set-mirati-therapeutics-inc-mrtx-target-price-at-14-75.html.
About Mirati Therapeutics
Mirati Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The companys clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors.
Receive News & Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.